Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Sr One
AddedFeb 13, 2024
UpdatedJun 28, 2026
Sr One

Sr One

Operating

SR One, GlaxoSmithKline's venture arm, globally invests in innovative life science companies impacting healthcare.

Location
Conshohocken, PA, US
Founded
1985
Firm
Compare
Portfolio
Employees
Website

SR One, the venture capital arm of GlaxoSmithKline, focuses on investing in innovative life science companies globally. The firm primarily targets Series A and Series B funding rounds, with additional investments in later stages such as Series C and D. SR One's investment strategy is centered on backing companies with strong fundamentals and novel approaches to addressing diseases, aiming to translate cutting-edge science into transformative medical treatments.

Notable portfolio companies include Adarx Pharmaceuticals, Avalyn Pharma, Nimbus Therapeutics, and Odyssey Therapeutics. The firm is led by experienced partners who bring a wealth of industry expertise and connections, enhancing their ability to support portfolio companies beyond capital investment. SR One offers a unique "back-and-build" approach, providing strategic guidance and leveraging its extensive network to help startups navigate the complexities of drug development and commercialization.

Sr One - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments64
Current Portfolio Count34
Total Portfolio Exits3

Top Investment Stages

Series B22 (37.3%)
Series A20 (33.9%)
Series C9 (15.3%)
Series D5 (8.5%)
Series Unknown3 (5.1%)

Stage Mix

Series B 37%Series A 34%Series C 15%Series D 8%Series Unknown 5%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Odyssey Therapeutics logo

Odyssey Therapeutics

Avalyn Pharma logo

Avalyn Pharma

Nimbus Therapeutics logo

Nimbus Therapeutics

Fore Biotherapeutics logo

Fore Biotherapeutics

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Rezo Therapeutics logo

Rezo Therapeutics

Ancora Biotech logo

Ancora Biotech

Dren Bio logo

Dren Bio

Simcha Therapeutics logo

Simcha Therapeutics

Nomic Bio logo

Nomic Bio

HotSpot Therapeutics logo

HotSpot Therapeutics

ARS Pharmaceuticals logo

ARS Pharmaceuticals

Biotheryx logo

Biotheryx

River 2 Renal logo

River 2 Renal

River 3 Renal logo

River 3 Renal

Palleon Pharmaceuticals logo

Palleon Pharmaceuticals

Tranquis Therapeutics logo

Tranquis Therapeutics

Morphic Therapeutic logo

Morphic Therapeutic

Progyny logo

Progyny

Spero Therapeutics logo

Spero Therapeutics

Arch Oncology logo

Arch Oncology

Second Genome logo

Second Genome

Navitor Pharmaceuticals logo

Navitor Pharmaceuticals

Bird Rock Bio logo

Bird Rock Bio

Agtc logo

Agtc

Sr One - Classification

Also Known As
  • Sr One Limited
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 8 more industry codes
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 541000Professional, Scientific, and Technical Services
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 7300Business Services
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end